Palmitoylethanolamide (PEA)—‘Promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma

J.M. Keppel Hesselink, D.J. Kopsky, R.F. Witkamp

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

Palmitoylethanolamide (N-palmitoylethanolamine or PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signalling molecules. Earliest reports on the anti-inflammatory and immune modulating properties of PEA date back to 1957 when its isolation from soy lecithin, peanut meal, and egg yolk was reported. PEA is structurally related to anandamide and other endocannabinoids and possesses similar pathways for synthesis and breakdown. However, instead of being an endocannabinoid per se, PEA may be called a ‘promiscuous’ compound. It does not bind to cannabinoid receptors but interacts with several other receptors and non-receptor targets. This rather complex biology has indisputably contributed to the initially slow development of PEA, which witnessed a revival around 1993 with the seminal work of the late Rita Levi-Montalcini. Presently the compound is receiving increasing attention as a drug or nutraceutical against chronic pain, inflammation and degenerative diseases of the central nervous system. In this paper we review the development and pharmacology of this remarkable lipid mediator with its pleiotropic and ‘promiscuous’ character. The history of PEA exemplifies an evolving paradigm shift in pharma and nutrition from ‘single-target’ to ‘multiple-target’ approaches and provides new perspectives for future development in these fields.
Original languageEnglish
Pages (from-to)19-25
JournalPharmaNutrition
Volume2
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

peanut meal
central nervous system diseases
Non-Steroidal Anti-Inflammatory Agents
analgesics
pharmacology
amides
egg yolk
phosphatidylcholines
functional foods
pain
inflammation
nutrition
fatty acids
Biological Sciences
drugs
history
receptors
synthesis
lipids
Endocannabinoids

Cite this

@article{81e004f371e947029f27ac71caa2560c,
title = "Palmitoylethanolamide (PEA)—‘Promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma",
abstract = "Palmitoylethanolamide (N-palmitoylethanolamine or PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signalling molecules. Earliest reports on the anti-inflammatory and immune modulating properties of PEA date back to 1957 when its isolation from soy lecithin, peanut meal, and egg yolk was reported. PEA is structurally related to anandamide and other endocannabinoids and possesses similar pathways for synthesis and breakdown. However, instead of being an endocannabinoid per se, PEA may be called a ‘promiscuous’ compound. It does not bind to cannabinoid receptors but interacts with several other receptors and non-receptor targets. This rather complex biology has indisputably contributed to the initially slow development of PEA, which witnessed a revival around 1993 with the seminal work of the late Rita Levi-Montalcini. Presently the compound is receiving increasing attention as a drug or nutraceutical against chronic pain, inflammation and degenerative diseases of the central nervous system. In this paper we review the development and pharmacology of this remarkable lipid mediator with its pleiotropic and ‘promiscuous’ character. The history of PEA exemplifies an evolving paradigm shift in pharma and nutrition from ‘single-target’ to ‘multiple-target’ approaches and provides new perspectives for future development in these fields.",
author = "{Keppel Hesselink}, J.M. and D.J. Kopsky and R.F. Witkamp",
year = "2014",
doi = "10.1016/j.phanu.2013.11.127",
language = "English",
volume = "2",
pages = "19--25",
journal = "PharmaNutrition",
issn = "2213-4344",
publisher = "Elsevier BV",
number = "1",

}

Palmitoylethanolamide (PEA)—‘Promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma. / Keppel Hesselink, J.M.; Kopsky, D.J.; Witkamp, R.F.

In: PharmaNutrition, Vol. 2, No. 1, 2014, p. 19-25.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Palmitoylethanolamide (PEA)—‘Promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma

AU - Keppel Hesselink, J.M.

AU - Kopsky, D.J.

AU - Witkamp, R.F.

PY - 2014

Y1 - 2014

N2 - Palmitoylethanolamide (N-palmitoylethanolamine or PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signalling molecules. Earliest reports on the anti-inflammatory and immune modulating properties of PEA date back to 1957 when its isolation from soy lecithin, peanut meal, and egg yolk was reported. PEA is structurally related to anandamide and other endocannabinoids and possesses similar pathways for synthesis and breakdown. However, instead of being an endocannabinoid per se, PEA may be called a ‘promiscuous’ compound. It does not bind to cannabinoid receptors but interacts with several other receptors and non-receptor targets. This rather complex biology has indisputably contributed to the initially slow development of PEA, which witnessed a revival around 1993 with the seminal work of the late Rita Levi-Montalcini. Presently the compound is receiving increasing attention as a drug or nutraceutical against chronic pain, inflammation and degenerative diseases of the central nervous system. In this paper we review the development and pharmacology of this remarkable lipid mediator with its pleiotropic and ‘promiscuous’ character. The history of PEA exemplifies an evolving paradigm shift in pharma and nutrition from ‘single-target’ to ‘multiple-target’ approaches and provides new perspectives for future development in these fields.

AB - Palmitoylethanolamide (N-palmitoylethanolamine or PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signalling molecules. Earliest reports on the anti-inflammatory and immune modulating properties of PEA date back to 1957 when its isolation from soy lecithin, peanut meal, and egg yolk was reported. PEA is structurally related to anandamide and other endocannabinoids and possesses similar pathways for synthesis and breakdown. However, instead of being an endocannabinoid per se, PEA may be called a ‘promiscuous’ compound. It does not bind to cannabinoid receptors but interacts with several other receptors and non-receptor targets. This rather complex biology has indisputably contributed to the initially slow development of PEA, which witnessed a revival around 1993 with the seminal work of the late Rita Levi-Montalcini. Presently the compound is receiving increasing attention as a drug or nutraceutical against chronic pain, inflammation and degenerative diseases of the central nervous system. In this paper we review the development and pharmacology of this remarkable lipid mediator with its pleiotropic and ‘promiscuous’ character. The history of PEA exemplifies an evolving paradigm shift in pharma and nutrition from ‘single-target’ to ‘multiple-target’ approaches and provides new perspectives for future development in these fields.

U2 - 10.1016/j.phanu.2013.11.127

DO - 10.1016/j.phanu.2013.11.127

M3 - Article

VL - 2

SP - 19

EP - 25

JO - PharmaNutrition

JF - PharmaNutrition

SN - 2213-4344

IS - 1

ER -